Trial Profile
The Addition of Etanercept to Standard GVHD Prophylaxis in Patients Undergoing a Full Intensity Allogeneic Hematopoietic Stem Cell Transplant for the Prevention of Transplant Related Complications.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 02 Oct 2012 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 02 Mar 2010 Planned end date changed from 1 Aug 2010 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 19 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.